Company profile
Shattuck Labs, Inc.
NASDAQ:STTKBiotechnology: Pharmaceutical Preparations
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07753850 | phase2 | not_yet_recruiting | 2026-10-01 | 2028-07-01 | Shattuck Labs, Inc. | A Study of SL-325 in Crohn's Disease Patients |
| NCT04502888 | phase1 | terminated | 2020-09-17 | 2022-04-08 | Shattuck Labs, Inc. | Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin |
| NCT04406623 | phase1 | completed | 2020-06-29 | 2023-02-02 | Shattuck Labs, Inc. | Phase 1 Study of SL-172154 (SIRPĪ±-Fc-CD40L) in Subjects With Ovarian Cancer |
| NCT07158437 | phase1 | active_not_recruiting | 2025-09-18 | 2026-07-01 | Shattuck Labs, Inc. | Phase 1 Study of SL-325 in Healthy Volunteers |
| NCT05275439 | phase1 | terminated | 2022-03-17 | 2025-02-06 | Shattuck Labs, Inc. | Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML |
FDA applications (0)
No records yet.